No abstract

We report the first successful transplantation of cryopreserved ovarian cortical tissue into heavily irradiated tissues in a patient who had received sterilizing pelvic radiotherapy (54 Gy) and 40 weeks of intensive high-dose chemotherapy for the treatment of Ewing’s sarcoma 14 years earlier. Repeated transplantation procedures were required to obtain fully functional follicular development. Enlargement of the transplants over time and increase of the size of the uterus were demonstrated on sequential ultrasonographic examinations. Eggs of good quality that could be fertilized in vitro were obtained only after a substantial incremental increase of the amount of ovarian tissue transplanted. Single embryo replacement resulted in a normal pregnancy and the birth of a healthy child by cesarean section at full-term. No neonatal or maternal postoperative complications occurred. Women facing high-dose pelvic radiotherapy should not be systematically excluded from fertility preservation options, as is currently the trend.

This treatment regimen for children with Hodgkin lymphoma, when applied as a multi-institutional regimen, had poorer outcome than our previously reported preliminary data and was inferior to the EFS reported in high-income countries. The major contributor adversely affecting EFS in this report is abandonment of therapy. Given these results, AHOPCA initiated a concerted effort to decrease abandonment of therapy.

Low breast cancer screening rates are often found among ethnic minority groups and those born outside the host country. This is of particular concern for high-risk groups, who should benefit from ongoing trials aimed at optimizing screening strategies for breast, as well as ovarian cancer. Both of these issues are germane for Jewish women in Europe. We systematically review the literature concerning breast cancer early detection practices (BCEDP) among Jewish women, and examine European surveillance studies of high-risk for breast and/or ovarian cancer that had imaging in the surveillance protocol, in order to assess the likelihood of adequately including women from minority ethnic groups. No studies were found about BCEDP among Jewish women in Europe. Twenty-one research groups from Israel or the US addressed BCEDP among Jewish women. Some Jewish women in the US and Israel, including recent immigrants, are under-screened. Twenty-four research groups reported imaging surveillance of women at increased risk for breast and/or ovarian cancer in Europe. There was a clear benefit to magnetic resonance imaging and/or more intensive screening for women with increased breast cancer risk. Some of these surveillance studies considered ethnic minority groups at high risk, including Jewish women, but none provided adequate outreach to ensure that these groups were included in their programs. The specific screening needs of Jewish and other high-risk ethnic minority groups in Europe have not been met regarding breast and ovarian cancer. A European-wide, population-based approach is suggested, with cultural sensitivity being vital for these efforts.

No abstract